Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws

Oral Dis. 2014 Jul;20(5):446-52. doi: 10.1111/odi.12150. Epub 2013 Jul 10.

Abstract

Aim: To determine the plasma and saliva levels of IL-6 in patients with bisphosphonate-related osteonecrosis of the jaws (BRONJ) and to investigate whether there is a correlation between more advanced stages of BRONJ and levels of IL-6.

Material and methods: We studied three groups: group 1 consisted of 30 patients with BRONJ due to intravenous bisphosphonates (ivBP), group 2 consisted of 25 patients treated with ivBP but without BRONJ, and group 3 consisted of 15 healthy controls. In each case, we assayed plasma and saliva IL-6 samples using an ELISA test.

Results: Significantly, higher IL-6 values were found in both saliva and plasma in group 1 vs groups 2 and 3 (P < 0.01). Group 1 showed no differences in plasma or saliva IL-6 according to patient gender (P > 0.05), type of tumor, BRONJ location, etiology of BRONJ, or disease stage (P > 0.05). We found higher plasma and saliva IL-6 values in the more advances stages of BRONJ, although the differences were not statistically significant.

Conclusions: Plasma and saliva IL-6 values were higher in our patients with BRONJ than in controls and therefore might be a useful tool for monitoring the severity of BRONJ.

Keywords: bisphosphonates; interleukin-6; osteonecrosis of the jaws.

MeSH terms

  • Aged
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / blood
  • Bisphosphonate-Associated Osteonecrosis of the Jaw / metabolism*
  • Diphosphonates / administration & dosage
  • Female
  • Humans
  • Interleukin-6 / analysis*
  • Interleukin-6 / blood*
  • Male
  • Saliva / chemistry*

Substances

  • Diphosphonates
  • IL6 protein, human
  • Interleukin-6